Risk Factors for Hepatotoxicity in HIV-1–Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine
نویسندگان
چکیده
E. H. Gisolf, C. Dreezen, S. A. Danner, J. L. F. Weel, and G. J. Weverling, for the Prometheus Study Group National AIDS Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine and AIDS, Department of Internal Medicine, and Departments of Clinical Virology/Medical Microbiology and Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Institute for Tropical Medicine, Antwerp, Belgium
منابع مشابه
Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients
Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic vis...
متن کاملSurvey of Antiretroviral Drug Resistance Pattern Among HIV-Infected Patients with Treatment Failure in Iran
Submit Manuscript | http://medcraveonline.com Abbreviations: ART: Antiretroviral Therapy; NNRTI: NonNucleoside Reverse Transcriptase Inhibitor; NRTI: Nucleoside/N Ucleotide Reverse Transcriptase Inhibitor; PI: Protease Inhibitor; AZT: Zidovudine; D4T: Stavudine; DDI: Didanosine; TDF: Tenofovir Disoproxil Fumarate; EFV: Efavirenz; NVP: Nevirapine; ETR: Etravirine; LPV/R: Lopinavir and Ritonavir;...
متن کاملUnexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
OBJECTIVES: Rifampin is a potent inducer of the cytochrome P450 3A4 isoenzyme (CYP3A4) that metabolizes most protease inhibitor (PI) antiretrovirals. This study was designed to evaluate the steady-state pharmacokinetics and tolerability of the coadministration of the PIs saquinavir and ritonavir (a CYP3A4 inhibitor used as a pharmacoenhancer of other PIs) and rifampin when coadministered in hea...
متن کاملSafety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
Human immunodeficiency virus type 1 (HIV-1) protease inhibitors have dramatically improved treatment options for HIV infection, but frequent dosing may impact adherence to highly active antiretroviral treatment regimens (HAART). Previous studies demonstrated that combined therapy with ritonavir and saquinavir allows a decrease in frequency of saquinavir dosing to twice daily. In this study, we ...
متن کاملViral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed no difference in the mean+/-SD e...
متن کامل